Post hoc analysis of moderately and severely affected patients ( baseline National Institutes of Health Stroke Scale , 7 and 10 ) showed greater National Institutes of Health Stroke Scale improvements in the 3 mg/d cutamesine group when compared with placebo ( P = 0.034 and P = 0.038 , respectively ) .